[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,931,350
  • Shares Outstanding, K 116,106
  • Annual Sales, $ 0 K
  • Annual Income, $ -359,640 K
  • EBIT $ -502 M
  • EBITDA $ -511 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.07

Options Overview Details

View History
  • Implied Volatility 82.76% (+2.75%)
  • Historical Volatility 61.47%
  • IV Percentile 70%
  • IV Rank 23.98%
  • IV High 170.22% on 08/12/25
  • IV Low 55.17% on 04/30/26
  • Expected Move (DTE 2) 2.64 (7.88%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 5,627
  • Volume Avg (30-Day) 10,775
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 196,556
  • Open Int (30-Day) 199,290
  • Expected Range 30.80 to 36.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.21
  • Number of Estimates 9
  • High Estimate $-0.94
  • Low Estimate $-1.38
  • Prior Year $-0.58
  • Growth Rate Est. (year over year) -108.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.72 +2.17%
on 07/28/26
42.79 -21.87%
on 07/07/26
-6.11 (-15.45%)
since 06/29/26
3-Month
27.16 +23.09%
on 06/11/26
42.79 -21.87%
on 07/07/26
+2.10 (+6.70%)
since 04/29/26
52-Week
22.96 +45.61%
on 09/17/25
43.15 -22.53%
on 11/12/25
+0.52 (+1.58%)
since 07/29/25

Most Recent Stories

More News
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

VKTX : 33.43 (-1.27%)
Viking Therapeutics Prepares to Defend Its Obesity Trial Timeline Against Growing Skepticism

Barchart Research What to Expect from VKTX Earnings VKTX Generated July 28, 2026 Current Price $33.86 EPS Estimate $$-1.21 Consensus Rating Strong Buy Average Move 8.96% Viking Therapeutics Prepares to...

VKTX : 33.43 (-1.27%)
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization

VKTX : 33.43 (-1.27%)
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026

Conference Call Scheduled for   Wednesday, July 29, at 4:30 p.m. Eastern Time  

VKTX : 33.43 (-1.27%)
Viking Therapeutics Earnings Hinge on Whether Pipeline Progress Can Offset Another Quarter Without Revenue

Barchart Research What to Expect from VKTX Earnings VKTX Generated July 21, 2026 Current Price $37.95 EPS Estimate $$-1.21 Consensus Rating Strong Buy Average Move 8.96% Viking Therapeutics Earnings Hinge...

VKTX : 33.43 (-1.27%)
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

NEW YORK , July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX)...

VKTX : 33.43 (-1.27%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 167.26 (+4.93%)
CLDX : 37.51 (+5.42%)
PGEN : 5.45 (-1.45%)
NVO : 51.58 (+1.22%)
AKAM : 107.41 (-3.92%)
SNEX : 72.07 (-2.98%)
ORCL : 117.74 (-1.85%)
ABBV : 263.30 (+0.04%)
GDXJ : 94.98 (-1.86%)
RSP : 215.73 (-0.90%)
VKTX : 33.43 (-1.27%)
LLY : 1,210.02 (-0.87%)
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

VKTX : 33.43 (-1.27%)
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer

Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval

VKTX : 33.43 (-1.27%)
Viking Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO , May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic...

VKTX : 33.43 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 35.18
2nd Resistance Point 34.60
1st Resistance Point 34.01
Last Price 33.43
1st Support Level 32.84
2nd Support Level 32.26
3rd Support Level 31.67

See More

52-Week High 43.15
Fibonacci 61.8% 35.44
Last Price 33.43
Fibonacci 50% 33.05
Fibonacci 38.2% 30.67
52-Week Low 22.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.